17,261 trials
Osteoarthritis, Knee
Primary: Change From Baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score in JointStem Group — -20.121 score on a scale
Duchenne Muscular Dystrophy
Primary: Incidence of Adverse Events as Assessed by CTCAE v4.0. — 3; 4; 4; 5 Participants
Progressive Familial Intrahepatic Cholestasis (PFIC)
Primary: Change From Baseline to Endpoint (Week 13) in Fasting sBA Level — -23; 18; -38 umol/L
Lupus Nephritis
Primary: Percentage of Patients With Complete Renal Response (CRR) at Week 52 — 38.32; 44.95; 44.56; 48.33 Percentage of Participants — p=0.7271
Rheumatoid Arthritis
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 91; 1; 8; 3 Participants
COVID 19 · Coronavirus
Primary: Number of Participants Who Met Clinical Worsening — 0; 6 Participants
Essential Tremor
Primary: Evaluate the Occurrence and Severity of Treatment Emergent AEs. — 13; 9; 2; 2 participants
Labor; Forced or Induced, Affecting Fetus or Newborn
Primary: Number of Participants With Vaginal Delivery Within 24 Hours — 50; 55 Participants
Breast Cancer · Triple Negative Breast Cancer
Primary: Tumor Response — 22 Participants
Alzheimer Disease
Primary: Treatment Related Adverse Events — 6; 3 Participants
Smoking Cessation · Social Stress
Primary: Accrual Percentage — 8.9 percentage of participants enrolled
Atopic Dermatitis
Primary: Change From Baseline (Week 0) to Week 8 in Eczema Area and Severity Index (EASI) Score. — -5.0; -4.9; -5.8; -7.6 score on a scale — p=<0.0001
Psoriasis
Primary: Percent Change From Baseline in 4 Week Target Plaque Severity Score x Target Plaque Area in Cohort 2 — -66.6; -66.0; -38.1 Percent change — p=0.0007
Prostate Cancer
Primary: Immune Responses to Treatment With Sipuleucel-T (With or Without Radium-223) Measured by Peripheral PA2024 T-cell Proliferation — 7.0; 22.4 fold change
Klinefelter Syndrome
Primary: Motor Function/Strength — 86; 81; 92; 89 score on a scale — p=0.005